Search
Belapectin
go.drugbank.com/drugs/DB15125InvestigationalBelapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).
Navtemadlin
go.drugbank.com/drugs/DB15299InvestigationalNavtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Furafylline
go.drugbank.com/drugs/DB14029ExperimentalFurafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for [theophylline].
PF-06459988
go.drugbank.com/drugs/DB14768InvestigationalPF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Parathyroid Hormone-Related Protein 1-36
go.drugbank.com/drugs/DB16278InvestigationalParathyroid Hormone-Related Protein 1-36 is under investigation in clinical trial NCT00853723 (Comparison Study of Pthrp and PTH to Treat Osteoporosis).
YS-ON-001
go.drugbank.com/drugs/DB17291InvestigationalYS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Etamicastat
go.drugbank.com/drugs/DB15288InvestigationalEtamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).
Bevifimod
go.drugbank.com/drugs/DB15301InvestigationalBevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
ALT-801
go.drugbank.com/drugs/DB15386InvestigationalALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).